TWI343256B - Cornea-conjunctiva disorder treating agent - Google Patents
Cornea-conjunctiva disorder treating agent Download PDFInfo
- Publication number
- TWI343256B TWI343256B TW093132101A TW93132101A TWI343256B TW I343256 B TWI343256 B TW I343256B TW 093132101 A TW093132101 A TW 093132101A TW 93132101 A TW93132101 A TW 93132101A TW I343256 B TWI343256 B TW I343256B
- Authority
- TW
- Taiwan
- Prior art keywords
- salt
- corneal
- ylmethoxy
- methoxy
- benzyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1343256 九、發明說明: 【發明所屬之技術領域】 本發明係相關於以5-[4-( 6 -甲氧基-1-甲基-1H -苯并咪唑 -2-基甲氧基)苄基]四氫噻唑_2,4-二酮或其鹽作爲有效成分 之角結膜障害之治療劑。 【先前技術】 角膜係一直徑約1 cm、厚約1 mm的透明無血管之組織, 又’結膜係覆蓋角膜邊緣稍後方的眼球的表面和眼瞼內面 之黏膜’角膜和結膜對視覺機能有重要的影響。角膜潰瘍、 角膜炎、結膜炎、乾眼症等各種疾病引起的角結膜障害, 若因某些因素導致延遲修復或無法修復而轉移,因角膜和 結膜爲相連組織,對上皮的正常組織產生不良影響,且可 能傷及實質和內皮的結構和機能。近年,隨著細胞生物學 的發展’已了解細胞的分裂•移動•黏著•伸展•分化等 相關因素,而這些因素在角膜障害的修復過程中扮演重要 的角色(非特許文獻1、非特許文獻2 )。 另一方面,特許文獻1揭示5-[4-(6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基)苄基]四氫噻唑-2,4-二酮係糖尿 病、高血糖症等胰島素抵抗性引起的疾病或骨關節炎、類 風濕性關節炎等炎症性疾病的有效治療藥,又,特許文獻 2及特許文獻3揭示上述化合物的鹽酸鹽的溶解性較其自 由體(不形成鹽之化合物)的溶解性明顯地更佳,發揮優 越的經口吸收性。 惟,無探討上述化合物對角結膜障害等眼疾病的藥理作 用之報告。 1343256 【特許文獻1】特許第2976885號公報 【特許文獻2】特開200 1 -3 997 6號公報 【特許文獻3】特開2002-220336號公報 【非特許文獻1】臨眼,46,7 3 8_743 ( 1 992 ) 【非特許文獻2】眼_手術,5,7 1 9 - 7 2 7 ( 1 9 9 2 ) 【發明內容】 【發明之目的】 本發明的目的係探索雜環化合物5_ [4-(6-甲氧基-1-甲基 -1H-苯并咪唑-2-基甲氧基)苄基]四氫噻唑-2,4-二酮或其 鹽之新穎醫藥用途。 本案發明者們爲要探索上述化合物之新穎醫藥用途,經 精心硏究而在角膜障害的治癒效力試驗中,發現上述化合 物對角膜障害可發揮優越的改善效果,而完成本發明。 亦即,本發明係以5-[4-(6 -甲氧基-1-甲基-1H -苯并咪哩 -2 -基甲氧基)苄基]四氫噻唑_2,4 -二酮或其鹽作爲有效成 分的乾眼症、角膜潰瘍、角膜炎、結膜炎' 點狀表層角膜 症' 角膜上皮缺損、結膜上皮缺損、乾性角結膜炎、上輪 部角結膜炎、絲狀角膜炎等角結膜障害之治療劑。 本發明之5-[4-(6-甲氧基·1-甲基-1H-苯并咪唑-2-基甲氧 基)苄基]四氫噻唑-2,4-二酮(以下簡稱爲(本化合物)) 係如下面化學結構式(1)所表不之縮合雜環化合物,又, 其鹽類無特別的限制,爲醫藥許可的鹽即可,例如和鹽酸、 硝酸、硫酸等無機酸形成的鹽,或和鈉、鉀、鈣等鹼金屬 或鹼土類金屬形成的鹽等。以鹽酸鹽較佳。又,本發明之 鹽亦包含本化合物的第四級銨鹽。且,本化合物存有幾何 1343256 異又
圍 範 明 發 本 損點 膜' 結炎 或膜 膜結 角、 致炎 導膜 素角 因、 種瘍 各潰 因膜 指角 係 、 害症 障眼 膜乾 結如 角例 中, 明態 發狀 本的 傷 狀表層角膜症、角膜上皮缺損、結膜上皮缺損、乾性角結 膜炎、上輪部角結膜炎、絲狀角膜炎等。 本發明的角結膜障害治療劑可由經口或非經口方式投 與。投與劑型例如點眼劑、眼軟膏、注射劑、錠劑、膠囊 劑、顆粒劑、散劑等。尤以點眼劑較理想。可採用泛用的 技術進行製劑化。例如,可依需求使用氯化鈉、濃甘油等 等張劑、磷酸鈉、醋酸鈉等緩衝劑、聚環氧乙烷山梨糖醇 酐一油酸酯、聚氧硬脂酸40、聚環氧乙烷硬化蓖麻油等界 面活性劑、檸檬'酸鈉、EDTA-鈉安定化劑、氯化苄烷銨、 對胺基苯甲酸等防腐劑等,調製成點眼劑。其pH爲眼科製 劑可容許的範圍爲佳,在4-8的範圍較佳。 眼軟膏係使用白色凡士林、液態蠟等泛用的基劑而調 製。又’錠劑、膠囊、顆粒劑、散劑等經口劑可依需求添 加乳糖、結晶纖維素 '澱粉、植物油等增量劑、硬脂酸鎂、 滑石等潤滑劑、羥丙基纖維素、聚乙烯吡略烷酮等黏合劑、 羧甲基纖維素鈣、低取代羥丙基甲基纖維素等崩解劑、羥 丙基甲基纖維素、聚乙二醇(Macrogol)、矽樹脂等包覆劑、 1343256 明膠皮膜等皮膜劑等進行調製。 可依症狀、年齡、劑型適當地選擇給藥量,惟點眼劑通 常爲0.0001-1% (w/v),較理想爲0.001〜1% (w/v)的量 1曰中分成1〜數次投與。又,若爲經口劑通常丨日量爲 0.1〜5000mg,較理想爲i~i〇〇〇mg分成1-•數次投與。 【發明的效果】 如後述般’實施角膜障害的治癒效力試驗時,因本化合 物在乾眼模式中發揮優越的促進治療效果,有助於作爲乾 眼症、角膜潰瘍、角膜炎' 結膜炎、點狀表層角膜症.、角 膜上皮缺損、結膜上皮缺損、乾性角結膜炎、上輪部角結 膜炎、絲狀角膜炎等角結膜障害的治療劑。 【實施方式】 【實施發明之最佳型態】 以下所示爲製劑例及藥理試驗的結果,爲要更清楚了解 本發明而進行這些舉例,惟本發明的範圍不受限於這些舉 例。 〔製劑例〕 以下所示爲使用5-[4-(6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基)苄基]四氫噻唑-2,4-二酮(本化合物)的代表 製劑例》 製劑例1 1 Omg 900mg 適量 100ml 中 本化合物 氯化鈉 滅菌純化水 1343256 經由改變本化合物之添加量’可調製濃度〇. Ο 〇丨% (w/v)、0.01% (w/v)、0.03% (w/v)、0.1¾ (w/v) 0.3% ( w/v ) ' 1.0% (w/v) ' 3.0% (w/v)的點眼劑。 製劑例2 100ml 中 本化合物 lOOmg 氯化納 8 0 〇 m g 磷酸氫二鈉 lOOmg 憐酸二氫鈉 適量 滅菌純化水 適量 經由改變本化合物之添加量’可調製濃度0.1% ( w/v )、 0.3¾ (w/v) > 0.5% ( w/v) 、1.5% ( w/v) '3.0% ( w/v ) 的點眼劑。 製劑例3 100g 中 本化合物 0.3 g 液態石蠟 1 0.0 g 白色凡士林 適量 經由改變本化合物之添加量’可調製濃度1 % ( W/V )' 3 % ( w/v )的眼軟膏。 〔藥理試驗〕 角膜障害的治癒效力試驗 使用雄性SD老鼠,以藤原等的方法(In vest. Ophthalmol. Vis. Sci42(I) : 96-100( 2001))爲基準,製作乾眼模式。 作成乾眼模式後,以宮田等的方法(眼科臨床醫報48( 2 ): 1343256 183-188 ( 1994))爲基準,評定角膜障害的治癒率。 (試驗方法) 在雄性SD老鼠的腹腔內,以35mg/kg的比例投與戊巴比 妥鈉進行全身麻醉。其次,取出眼窩外淚腺,經時2個月 使發生角膜障害》 之後,分別在單眼滴入本化合物的0.01%生理食鹽水溶 解液,另一眼滴入生理食鹽水(對照組),1日6次共進 行7日。 開始點眼的7日後,以螢光素染色角膜的障害部分。根 據下述的基準,評估有關角膜的上部 '中間部及下部中螢 光素染色的程度,從上述各部總計得分的平均値算出角膜 障害的改善率。 至於正常眼亦進行和上述相同的試驗,求出上述各部的 總計得分的平均値》 (評定基準) . 0 :無染色 1:稀疏染色,各點狀的染色部分分離 2 :中程度染色,部分的點狀染色部分相鄰接 3:密集染色,各點狀的染色部分相鄰接 (結果) 在生理食鹽水點藥組(對照組)中,以上述各部的總計 得分的平均値爲基準(改善率:〇% ),並根據下述計算式 算出’表1所示係本化合物的0.01%點藥組的改善率。又, 得分的平均値係各8例的平均。 改善率(% ) = {(對照組)一(本化合物.)} /障害度χ 1 〇〇 -10- 1343256 障害度={(對照組)一(正常眼)} (表1 ) 組 總計得分平均値 改善率(% ) 正常眼 2.9 4πχ 無 對照組 6.1 0 本化合物 4.4 5.3 (考察) 從上述使用老鼠的藥理試驗之結果可知,5-[4- ( 6-甲氧 基-1-甲基-1H -苯并咪唑-2-基甲氧基)苄基]四氫噻唑-2,4
-11 -
Claims (1)
1343256 .公告本; 修正頁 第93132101「角結膜障害之治療劑」專^利案 (2 0 1 0年1 2月1曰修正) 十、申請專利範圍: _ ^ 1.一種乾性角結膜炎之治療劑,其含有5-[4-(6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基)苄基]四氫噻唑-2,4-二 酮或其鹽作爲有效成分。 2 .如申請專利範圍第1項之治療劑,其中劑型係點眼劑或 眼軟膏。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003364864 | 2003-10-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200518750A TW200518750A (en) | 2005-06-16 |
TWI343256B true TWI343256B (en) | 2011-06-11 |
Family
ID=34510137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093132101A TWI343256B (en) | 2003-10-24 | 2004-10-22 | Cornea-conjunctiva disorder treating agent |
Country Status (16)
Country | Link |
---|---|
US (1) | US7358255B2 (zh) |
EP (1) | EP1679074B1 (zh) |
JP (1) | JP4217832B2 (zh) |
KR (1) | KR101154175B1 (zh) |
CN (1) | CN1870997B (zh) |
AT (1) | ATE490771T1 (zh) |
CA (1) | CA2543452C (zh) |
CY (1) | CY1111191T1 (zh) |
DE (1) | DE602004030470D1 (zh) |
DK (1) | DK1679074T3 (zh) |
ES (1) | ES2357801T3 (zh) |
PL (1) | PL1679074T3 (zh) |
PT (1) | PT1679074E (zh) |
SI (1) | SI1679074T1 (zh) |
TW (1) | TWI343256B (zh) |
WO (1) | WO2005039574A1 (zh) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060118520A (ko) * | 2003-10-29 | 2006-11-23 | 산텐 세이야꾸 가부시키가이샤 | 각결막장해 치료제 |
WO2006064825A1 (ja) * | 2004-12-14 | 2006-06-22 | Santen Pharmaceutical Co., Ltd. | ドライアイ治療剤 |
KR101409705B1 (ko) | 2005-11-28 | 2014-07-14 | 센주 세이야꾸 가부시키가이샤 | Ppar 아고니스트 함유 의약 |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
WO2008143254A1 (ja) * | 2007-05-21 | 2008-11-27 | Senju Pharmaceutical Co., Ltd. | PPARδアゴニスト含有医薬 |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
KR20100137417A (ko) * | 2008-02-25 | 2010-12-30 | 산텐 세이야꾸 가부시키가이샤 | 각막 상피 배리어 기능 항진제 |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JP5775070B2 (ja) * | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
MY161416A (en) | 2009-05-22 | 2017-04-14 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors |
US9249145B2 (en) * | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
AR081315A1 (es) * | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
ME02445B (me) | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
CA3178452A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264586B1 (en) | 1986-08-28 | 1991-04-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Hydantoin derivatives for treating complications of diabetes |
JP3072227B2 (ja) * | 1994-08-01 | 2000-07-31 | 株式会社クボタ | 田植機の粉粒体供給装置 |
JP3603129B2 (ja) | 1994-12-28 | 2004-12-22 | 株式会社三和化学研究所 | 糖尿病性角膜症の治療剤 |
IL118474A (en) | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
US6372750B2 (en) | 1996-07-01 | 2002-04-16 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases |
US5885997A (en) | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
US6114526A (en) | 1996-07-01 | 2000-09-05 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
HUP0301101A3 (en) | 1996-12-31 | 2009-03-30 | Reddy S Res Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
JPH11130675A (ja) * | 1997-08-29 | 1999-05-18 | Santen Pharmaceut Co Ltd | クロマン誘導体含有点眼液 |
EP0909558A3 (en) * | 1997-08-29 | 1999-10-27 | Santen Pharmaceutical Co., Ltd. | Chroman derivative containing ophthalmic solution |
JP2001039976A (ja) * | 1999-05-24 | 2001-02-13 | Sankyo Co Ltd | 縮合複素環化合物の塩酸塩 |
TWI284533B (en) * | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
JP2002220336A (ja) | 2000-11-22 | 2002-08-09 | Sankyo Co Ltd | 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬 |
JP4090013B2 (ja) | 2000-12-26 | 2008-05-28 | 第一三共株式会社 | 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物 |
KR20060118520A (ko) | 2003-10-29 | 2006-11-23 | 산텐 세이야꾸 가부시키가이샤 | 각결막장해 치료제 |
-
2004
- 2004-10-22 TW TW093132101A patent/TWI343256B/zh not_active IP Right Cessation
- 2004-10-22 US US10/576,719 patent/US7358255B2/en not_active Expired - Fee Related
- 2004-10-22 AT AT04793171T patent/ATE490771T1/de active
- 2004-10-22 CN CN2004800309819A patent/CN1870997B/zh not_active Expired - Fee Related
- 2004-10-22 PL PL04793171T patent/PL1679074T3/pl unknown
- 2004-10-22 KR KR1020067009936A patent/KR101154175B1/ko not_active IP Right Cessation
- 2004-10-22 DK DK04793171.2T patent/DK1679074T3/da active
- 2004-10-22 PT PT04793171T patent/PT1679074E/pt unknown
- 2004-10-22 ES ES04793171T patent/ES2357801T3/es active Active
- 2004-10-22 EP EP04793171A patent/EP1679074B1/en not_active Not-in-force
- 2004-10-22 CA CA2543452A patent/CA2543452C/en not_active Expired - Fee Related
- 2004-10-22 SI SI200431607T patent/SI1679074T1/sl unknown
- 2004-10-22 DE DE602004030470T patent/DE602004030470D1/de active Active
- 2004-10-22 WO PCT/JP2004/016063 patent/WO2005039574A1/ja not_active Application Discontinuation
- 2004-10-22 JP JP2004307544A patent/JP4217832B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-18 CY CY20111100206T patent/CY1111191T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1679074B1 (en) | 2010-12-08 |
CN1870997B (zh) | 2011-05-04 |
TW200518750A (en) | 2005-06-16 |
KR101154175B1 (ko) | 2012-06-14 |
CN1870997A (zh) | 2006-11-29 |
JP2005145961A (ja) | 2005-06-09 |
CY1111191T1 (el) | 2015-06-11 |
PT1679074E (pt) | 2011-03-03 |
EP1679074A4 (en) | 2009-03-25 |
KR20060100440A (ko) | 2006-09-20 |
ATE490771T1 (de) | 2010-12-15 |
DK1679074T3 (da) | 2011-03-21 |
US7358255B2 (en) | 2008-04-15 |
WO2005039574A8 (ja) | 2005-06-23 |
PL1679074T3 (pl) | 2011-05-31 |
US20070060628A1 (en) | 2007-03-15 |
WO2005039574A1 (ja) | 2005-05-06 |
SI1679074T1 (sl) | 2011-04-29 |
EP1679074A1 (en) | 2006-07-12 |
ES2357801T3 (es) | 2011-04-29 |
JP4217832B2 (ja) | 2009-02-04 |
CA2543452C (en) | 2012-03-13 |
CA2543452A1 (en) | 2005-05-06 |
DE602004030470D1 (de) | 2011-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI343256B (en) | Cornea-conjunctiva disorder treating agent | |
RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
EP2163548B1 (en) | Prophylactic or therapeutic agent for age-related macular degeneration | |
JP5087233B2 (ja) | 角結膜障害の予防または治療剤 | |
JP4922588B2 (ja) | 角結膜障害治療剤 | |
RU2423127C2 (ru) | Терапевтическое средство против роговично-конъюнктивального нарушения | |
WO2005108396A1 (ja) | 角結膜障害治療剤 | |
EP1790338A1 (en) | Therapeutic agent for keratoconjunctiva disorder | |
WO2005039571A1 (ja) | 角結膜障害治療剤 | |
JP2006104199A (ja) | 角結膜障害治療剤 | |
JP2005350451A (ja) | 角結膜障害治療剤 | |
JP2005162735A (ja) | 角結膜障害治療剤 | |
JP2007182435A (ja) | 角結膜障害治療剤 | |
WO2007114315A1 (ja) | 角結膜障害治療剤 | |
JP2004210692A (ja) | 眼科用治療組成物 | |
JP2008024699A (ja) | フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |